Abstract:Continuous loss of cardiomyocytes (CMs) is one of the fundamental characteristics of many heart diseases, which eventually can lead to heart failure. Due to the limited proliferation ability of human adult CMs, treatment efficacy has been limited in terms of fully repairing damaged hearts. It has been shown that cell lineage conversion can be achieved by using cell reprogramming approaches, including human induced pluripotent stem cells (hiPSCs), providing a promising therapeutic for regenerative heart medicine. Recent studies using advanced cellular reprogramming-based techniques have also contributed some new strategies for regenerative heart repair. In this review, hiPSC-derived cell therapeutic methods are introduced, and the clinical setting challenges (maturation, engraftment, immune response, scalability, and tumorigenicity), with potential solutions, are discussed. Inspired by the iPSC reprogramming, the approaches of direct cell lineage conversion are merging, such as induced cardiomyocyte-like cells (iCMs) and induced cardiac progenitor cells (iCPCs) derived from fibroblasts, without induction of pluripotency. The studies of cellular and molecular pathways also reveal that epigenetic resetting is the essential mechanism of reprogramming and lineage conversion. Therefore, CRISPR techniques that can be repurposed for genomic or epigenetic editing become attractive approaches for cellular reprogramming. In addition, viral and non-viral delivery strategies that are utilized to achieve CM reprogramming will be introduced, and the therapeutic effects of iCMs or iCPCs on myocardial infarction will be compared. After the improvement of reprogramming efficiency by developing new techniques, reprogrammed iCPCs or iCMs will provide an alternative to hiPSC-based approaches for regenerative heart therapies, heart disease modeling, and new drug screening.

Current advances in human-induced pluripotent stem cell-based models and therapeutic approaches for congenital heart disease

Inducing Pluripotency for Disease Modeling, Drug Development and Craniofacial Applications.

Human Induced Pluripotent Stem Cell for Modeling Cardiovascular Diseases.

Human-induced Pluripotent Stem Cells As Models for Rare Cardiovascular Diseases: from Evidence-Based Medicine to Precision Medicine

Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy

Deciphering Congenital Heart Disease Using Human Induced Pluripotent Stem Cells

Human Pluripotent Stem Cell-Derived Cardiac Cells: Application in Disease Modeling, Cell Therapy, and Drug Discovery

iPSC-Derived Cardiomyocytes as a Disease Model to Understand the Biology of Congenital Heart Defects

Investigating Inherited Heart Diseases Using Human Induced Pluripotent Stem Cell-Based Models

Human Induced Pluripotent Stem Cells for Inherited Cardiovascular Diseases Modeling

Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies

The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing

Advances in the Generation of Constructed Cardiac Tissue Derived from Induced Pluripotent Stem Cells for Disease Modeling and Therapeutic Discovery

Probing single ventricle heart defects with patient‐derived induced pluripotent stem cells and emerging technologies

Induced pluripotent stem cells for cardiovascular therapeutics: Progress and perspectives

The Role of Human-Induced Pluripotent Stem Cells in Studying Cardiac Channelopathies

Uncovering Inherited Cardiomyopathy With Human Induced Pluripotent Stem Cells

Human pluripotent stem cell-based models of heart development and disease

Advances in Cellular Reprogramming-Based Approaches for Heart Regenerative Repair

Modelling neurocardiac physiology and diseases using human pluripotent stem cells: current progress and future prospects

Non-viral reprogramming and induced pluripotent stem cells for cardiovascular therapy